Evidence map›Paper›PMID 29704233›Full record

ArticleJournal of endocrinological investigation2019

The mutational analysis in the diagnostic work-up of thyroid nodules: the real impact in a center with large experience in thyroid cytopathology.

E Macerola, T Rago, A Proietti, F Basolo, P Vitti

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of endocrinological investigation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Molecular Variants and Their Risks for Malignancy in Cytologically Indeterminate Thyroid Nodules.Thyroid : official journal of the American Thyroid Association · 2019
    Pooled it
  4. Trial
  5. Article
  6. Article
  7. Diagnostic utility ofEXCLI journal · 2024
    Review
  8. Review
  9. Article
  10. Review
  11. An overview of retrosternal goiter.Journal of endocrinological investigation · 2021
    Review
  12. Article
  13. Article
  14. Observational
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

E MacerolaDepartment of Surgical, Medical, Molecular Pathology and Critical Area (Anatomical Pathology Section), University of Pisa, via Savi 10, 56126, Pisa, Italy.ORCID http://orcid.org/0000-0002-0235-799X
T RagoDepartment of Clinical and Experimental Medicine (Endocrinology Section), University of Pisa, via Paradisa 2, 56124, Pisa, Italy.
A ProiettiDivision of Anatomical Pathology, University Hospital of Pisa, via Roma 57, 56126, Pisa, Italy.
F BasoloDepartment of Surgical, Medical, Molecular Pathology and Critical Area (Anatomical Pathology Section), University of Pisa, via Savi 10, 56126, Pisa, Italy.ORCID http://orcid.org/0000-0003-1657-5020
P VittiDepartment of Clinical and Experimental Medicine (Endocrinology Section), University of Pisa, via Paradisa 2, 56124, Pisa, Italy. paolo.vitti@med.unipi.it.

Funding

Italian government, PRIN grant 2015_HPMLFY
6 · The paper itself

Abstract

purposeFine-needle aspiration (FNA) cytology is a mainstay in the evaluation of thyroid nodules, but fails to reach reliable results in 25-30% of cases. The role of molecular markers in helping clinical decisions has been investigated for the last years, but their clinical usefulness is still unsettled.

methodsMutation analysis of BRAF, RAS genes and TERT promoter was performed in a series of 617 consecutive cytological specimens undergoing FNA.

resultsThe 617 nodules had the following cytological diagnosis: non diagnostic 22 (3.6%), benign 425 (68.9%), indeterminate 114 (18.5%), suspicious 11 (1.8%) and malignant 45 (7.3%). BRAF mutations were found in 31 cases (5.0%), all but two in suspicious and malignant nodules. RAS mutations were detected in 47 samples (7.6%): 25 benign (5.9%) and 19 indeterminate nodules (16.7%). TERT promoter mutation alone was detected in three samples. Histological outcome was available for 167 nodules, 81 of which proved malignant: all the 48 with suspicious or malignant cytology; 25 out of 56 (44.6%) with indeterminate and 8 out of 57 (14%) with benign cytology. BRAF mutations were associated with worse tumors pathological features. The presence of RAS mutations was indicative of follicular-patterned malignancies in 5 out of 8 benign nodules and 9 out of 11 indeterminate nodules.

conclusionsOur study established mutational rates for BRAF and RAS genes in a large series of FNA specimens. BRAF mutations were confirmed as highly specific but not able to improve cytological diagnosis, while RAS testing proved effective in assessing malignancy in nodules with indeterminate and benign cytology.

Indexed as

MutationAdultBiopsy, Fine-NeedleCytodiagnosisDNA Mutational AnalysisFemaleHumansMaleMiddle AgedPromoter Regions, GeneticProto-Oncogene Proteins B-rafras ProteinsTelomeraseThyroid GlandThyroid NeoplasmsThyroid NoduleBRAF protein, humanProto-Oncogene Proteins B-rafras ProteinsTelomeraseTERT protein, humanBRAFMolecular markerRASThyroid cancerThyroid cytology

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.